About Us
Stramsen Biotech
Our Vision
To be the global leader in plant-based pharmaceuticals, driving medical advancements that transform lives and shape the future of medicine.
Our Approach
Stramsen Biotech combines scientific expertise with advanced technologies to transform promising plant-based discoveries into innovative pharmaceuticals. We push scientific boundaries, explore new therapeutic frontiers, and develop solutions with the potential to address major unmet medical needs.
Our Portfolio
Total 33 Therapeutic Assets.
Wound Healing
SBX-1977, our lead candidate, targets active healing biology. FDA Pre-IND feedback supports IND submission and the proposed Phase 1 trial.
Prostate Cancer
SBX-1052 and SBX-1068:
Plant-based therapeutics under investigation for prostate enlargement and cancer, respectively.
Oncology
Our SBX 2021: Therapeutic candidate Controls and prevents the proliferation and metastasis of various cancer cells.
High Blood Pressure
SBX-2000 is our plant-based therapeutic candidate designed for the management of various cardiovascular diseases.
